NYSE:ASXC Stock Quote

ASXC stock results show that Asensus Surgical missed analyst estimates for earnings per share but beat on revenue for the second quarter of 2024.

Discover key robotics stocks to buy now for Q3. Learn about industry leaders in autonomous vehicles, robotic surgery and IoT integration.

KARL STORZ Endoscopy-America has agreed to acquire Asensus Surgical for $0.35 per share, representing a 67% premium. This acquisition will bolster KARL STORZ's robotic surgical market presence.

ASXC stock results show that Asensus Surgical missed analyst estimates for earnings per share and missed on revenue for the first quarter of 2024.

Top Wall Street analysts changed their outlook on these top names. For a complete view of all analyst rating changes, including upgrades and downgrades, please see our analyst ratings page.

These three penny stocks certainly look well-positioned to ride the next wave of growth higher in their diverse market niches.

ASXC stock results show that Asensus Surgical beat analyst estimates for earnings per share and beat on revenue for the fourth quarter of 2023.

Companies Reporting Before The Bell • Creative Realities (NASDAQ:CREX) is expected to report quarterly earnings at $0.02 per share on revenue of $16.47 million.

Thanks to the permanent relevance of medical innovations, investors ought to consider looking at these healthcare stocks.

With the innovation machinery running at full speed, investors may want to target these ideas for hottest tech stocks of 2024.

Although the concept of medical robotics stocks is incredibly risky, the sector also offers tremendous upside for the intrepid.